Methods of use of viral vectors to deliver antigen to dendritic cells
AssigneeThe Rockefeller University
InventorsRalph M. Steinman, Nina Bhardwaj
Life of this patent
Estimating the term…
Abstract
This invention relates to methods and compositions useful for delivering antigens to dendritic cells which are then useful for inducing T antigen specific cytotoxic T lymphocytes. This invention also provides assays for evaluating the activity of cytotoxic T lymphocytes. According to the invention, antigens are provided to dendritic cells using a viral vector such as influenza virus which may be modified to express non-native antigens for presentation to the dendritic cells. The dendritic cells which are infected with the vector are then capable of presenting the antigen and inducing cytotoxic T lymphocyte activity or may also be used as vaccines.
Claims11
Antigen presenting human dendritic cells prepared according to the method of:
- contacting, in vitro, proliferating or non-proliferating human dendritic cells with a nonreplicating viral vector comprising a gene sequence encoding an antigen which antigen is processed by said dendritic cells, and wherein said processed antigen is presented on the surface of said dendritic cells, and wherein said dendritic cells activate cytotoxic T cell responses that are at least as potent as those that develop in response to live virus.
An in vitro cell mixture comprising activated antigen-specific human cytotoxic T lymphocytes and dendritic cells which express on their surface a processed antigen encoded by a nonreplicating viral vecto , and wherein the cytotoxic T lymphocytes are activated by said processed antigen on said dendritic cells, and wherein said dendritic cells activate cytotoxic T cell responses that are at least as potent as those that develop in response to live virus.
A pharmaceutical composition comprising antigen presenting human dendritic cells prepared according to the method of:
- contacting, in vitro, proliferating or non-proliferating human dendritic cells with a nonreplicating viral vector comprising a gene sequence encoding an antigen, which antigen is processed by said dendritic cells to produce a processed antigen which is presented on the surface of said dendritic cells, and wherein said dendritic cells activate cytotoxic T cell responses that are at least as potent as those that develop in response to live virus, and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising activated antigen-specific human cytotoxic T lymphocytes and dendritic cells which express on their surface a processed antigen encoded by a nonreplicating viral vector, and wherein the cytotoxic T lymphocytes are activated by said processed antigen on said dendritic cells, and wherein said dendritic cells activate cytotoxic T cell responses that are at least as potent as those that develop in response to live virus, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.